

# Journal of Refractive Surgery

## Optical and clinical outcomes of an extended range of vision intraocular lens.

--Manuscript Draft--

<b>Manuscript Number:</b>	JRS-2021-257R1
<b>Full Title:</b>	Optical and clinical outcomes of an extended range of vision intraocular lens.
<b>Article Type:</b>	Original Article
<b>Order of Authors:</b>	Luis Fernández-Vega-Cueto, MD, PhD David Madrid-Costa, PhD Belén Alfonso-Bartolozzi, MD Fidel Vega, PhD María S Millán, PhD Jose F Alfonso, MD, PhD
<b>Order of Authors Secondary Information:</b>	
<b>Abstract:</b>	<p><b>Purpose:</b> To assess the in-vitro optical quality and halo formation of AcrySof® IQ Vivity™ intraocular lens (IOL) and to evaluate the clinical outcomes in patients who had bilateral implantation of this IOL.</p> <p><b>Methods:</b> The optical quality was evaluated with the PMTF optical bench (LAMBDA-X). Through-focus modulation transfer function area (TF-MTFa) curves between -5.00 and +2.00D were obtained for 3.00 and 4.5 mm of pupil apertures. The halo was assessed in-vitro with a test bench. The clinical study included 30 patients. Uncorrected (UDVA) and best-corrected distance visual acuity (CDVA), and binocular defocus curve were evaluated six months postoperatively.</p> <p><b>Results:</b> The TF-MTFa curve for 4.5 mm of pupil size show only one peak at distance focus (38.4 units). For 3.00 mm, the TF-MTFa showed a lower peak of MTFa (28.9 units), located at -0.70D, and an extended-depth-of-focus up to -2.20D. The halo formed was larger and somehow more intense compared to a standard-monofocal IOL. The clinical outcomes at 6 months revealed satisfactory visual acuity outcomes. All patients achieved a binocular CDVA of 0.1 logMAR or better. The mean visual acuity was better than 0.2 logMAR between +1.00 and -2.00D of defocus. At a vergence of -2.50 D the visual acuity was <math>0.31 \pm 0.09</math> logMAR.</p> <p><b>Conclusion:</b> The AcrySof® IQ Vivity™ IOL provided a good distance optical and visual quality and provided an extended range of focus of around 2.0 D, allowing to obtain an optimal or functional visual acuity up to 50-40 cm. The halo formed was low intensity.</p>
<b>Author Comments:</b>	
<b>Response to Reviewers:</b>	We have uploaded a file with the response to the reviewers

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

# Optical and clinical outcomes of an extended range of vision intraocular lens.

**Authors:** Luis Fernández-Vega-Cueto MD, PhD<sup>1</sup>, David Madrid-Costa PhD<sup>2</sup>, Belén Alfonso-Bartolozzi MD<sup>1</sup>, Fidel Vega PhD<sup>3</sup>, María S. Millán PhD<sup>3</sup>, José F. Alfonso MD, PhD<sup>1</sup>.

- 1.- Fernández-Vega Ophthalmological Institute, Oviedo, Spain.
- 2.- Optometry and Vision Department, Faculty of Optics and Optometry, Universidad Complutense de Madrid, Spain.
- 3.- Grupo de Óptica Aplicada y Procesado de Imagen (GOAPI), Department of Optics and Optometry, Universitat Politècnica de Catalunya BarcelonaTech, Terrassa, Spain.

**Address:**  
José F. Alfonso MD, PhD  
Instituto Oftalmológico Fernández-Vega  
Avda. Dres. Fernández-Vega 114. 33012 (Oviedo), Spain  
Telf: +34 985 245533 Fax: +34 985 233288  
e-mail: [j.alfonso@fernandez-vega.com](mailto:j.alfonso@fernandez-vega.com)

**Running head:** Optical and clinical outcomes of a new EDOF IOL.

34 **ABSTRACT**

35 **Purpose:** To assess the in-vitro optical quality and halo formation of AcrySof® IQ Vivity™  
36 intraocular lens (IOL) and to evaluate the clinical outcomes in patients who had bilateral  
37 implantation of this IOL.

38 **Methods:** The optical quality was evaluated with the PMTF optical bench (LAMBDA-X).  
39 Through-focus modulation transfer function area (TF-MTFa) curves between -5.00 and  
40 +2.00D were obtained for 3.00 and 4.5 mm of pupil apertures. The halo was assessed in-  
41 vitro with a test bench. The clinical study included 30 patients. Uncorrected (UDVA) and  
42 best-corrected distance visual acuity (CDVA), and binocular defocus curve were  
43 evaluated six months postoperatively.

44 **Results:** The TF-MTFa curve for 4.5 mm of pupil size show only one peak at distance  
45 focus (38.4 units). For 3.00 mm, the TF-MTFa showed a lower peak of MTFa (28.9 units),  
46 located at -0.70D, and an extended-depth-of-focus up to -2.20D The halo formed was  
47 larger and somehow more intense compared to a standard-monofocal IOL. The clinical  
48 outcomes at 6 months revealed satisfactory visual acuity outcomes. All patients  
49 achieved a binocular CDVA of 0.1 logMAR or better. The mean visual acuity was better  
50 than 0.2 logMAR between +1.00 and -2.00D of defocus. At a vergence of -2.50 D the  
51 visual acuity was  $0.31 \pm 0.09$  logMAR.

52 **Conclusion:** The AcrySof® IQ Vivity™ IOL provided a good distance optical and visual  
53 quality and provided an extended range of focus of around 2.0 D, allowing to obtain an  
54 optimal or functional visual acuity up to 50-40 cm. The halo formed was low intensity.

55

## 56 INTRODUCTION

57           Nowadays, more patients worldwide seek to obtain a wide range of good vision  
58 after cataract surgery, which allows them to be spectacles independent or reduce their  
59 dependence on it. Standard monofocal intraocular lenses (IOLs), which are the most  
60 commonly implanted after cataract surgery, provide an excellent distance visual  
61 performance; however, patients need spectacle correction for intermediate and near  
62 distances. In the last years, the designs and innovations in presbyopia-correcting IOLs  
63 have undergone a revolution over early bifocal IOLs, which provided a good distance  
64 and near visual quality, however showed a gap of poor quality at intermediate  
65 distance<sup>1,2</sup>. The first improvement to overcome this limitation was the bifocal IOLs  
66 designed with lower adds, which showed a better intermediate distance visual acuity  
67 than the previous models with higher adds<sup>2-4</sup>. However, this improvement did not fully  
68 satisfy the visual demands of a population increasingly interested in activities that  
69 require an intensively intermediate vision of good quality. Trifocal IOLs represented  
70 significant innovation to solve the shortcomings at the intermediate vision, which results  
71 in a higher prevalence of spectacle independence<sup>5-8</sup>. However, the incoming light  
72 distribution into multiples foci may induce a decrease in contrast sensitivity and  
73 dysphotopic phenomena such as halo and glare after surgery<sup>9-12</sup>. These drawbacks may  
74 not be well tolerated for some patients, leading to postoperative complaints and  
75 unsatisfactory results.

76           The technology to extend the range of vision, or equivalently, to extend the  
77 depth-of-focus (EDOF) in the image space, has recently emerged, aiming at providing  
78 good distance and intermediate visual acuity but only functional near visual acuity<sup>13</sup>.  
79 Theoretically, the EDOF IOLs have the advantage over other presbyopia-correcting

80 lenses, such as trifocal IOLs, of minimizing the visual disturbances and contrast  
81 sensitivity reduction induced by classic diffractive designs. The current scenario, with a  
82 great variety of presbyopia-correcting IOLs, makes it mandatory to perform further  
83 research focused on IOLs optical characterization and clinical studies to find the best IOL  
84 to meet the patients' needs providing the best quality of vision and the higher-level  
85 spectacle independence.

86         Recently an innovation has been developed in the field of EDOF IOLs, a non-  
87 diffractive extended-vision IOL (AcrySof® IQ Vivity™, Alcon, USA) with wavefront-  
88 shaping technology. The company's claim for this IOL is to extend the range of vision  
89 without visual disturbance. The current study aims to develop a comprehensive analysis  
90 of the optical and clinical performance of this new IOL. To this extent, we first assessed  
91 in vitro the optical quality and induced halo of the IOL. In a second phase, we analyzed  
92 the clinical outcomes in a sample of patients who undergone bilateral cataract surgery  
93 with AcrySof® IQ Vivity™ implantation.

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106

107 **METHODS**

108 **Intraocular lens**

109 The IOL studied was (AcrySof® IQ Vivity™, Alcon Labs., Inc., USA). It is a EDOF IOL  
110 that used a proprietary technology entitled wavefront-shaping (X-WAVE) by the  
111 manufacturer. According to the IOL's description by Khonen<sup>14</sup>, the IOL has a monofocal  
112 design from the periphery up to the central 2.2 mm diameter region. In this central area  
113 the IOL has a "plateau 1 μm high". This "plateau" creates a 2-surface transition that  
114 would induce a "stretching and shifting" of the wavefront. This way, theoretically, the  
115 new EDOF IOL creates a continuous extended focus segment rather than several focal  
116 points as happens with other diffractive EDOF IOLs<sup>15</sup>. The studied AcrySof® IQ Vivity™ is  
117 a 1-piece, hydrophobic aspheric IOL with a blue filter and ultraviolet protection. It has a  
118 total length of 13 mm and optical zone of 6 mm. The lens is available from +15.00 to  
119 +25.00 D in 0.50 D increments. The optical bench analysis was carried out with lenses of  
120 20.0 D base power.

121 **Optical performance**

122 The optical quality of the IOL was assessed using PMTF optical bench (Lambda-X,  
123 software version 1.13.6). This device and the experimental set-up have been described  
124 in detail in previous investigations with other IOLs<sup>5, 6, 16</sup>. The optical quality of the IOL  
125 was performed using a model eye, including an artificial cornea with +0.135 μm of 4th-  
126 order spherical aberration for a 5.0 mm pupil at the IOL plane. The wavelength of the  
127 light source was 546 nm.

128 For this study, the modulation transfer function (MTF) was obtained for a 3.0-  
129 and 4.5 mm diameter of aperture at the IOL plane. The focus extension was assessed  
130 from the through-focus (TF) MTF curves scanning the image space between +2.0 D and

131 -5.0 D defocus in 0.1 D steps. For a given focus position within the TF range, two MTF  
132 curves in the X and Y directions of the image plane were obtained and averaged. Then,  
133 the TF area under the MTF (MTFa) curves was calculated according to previous studies<sup>17-</sup>  
134 <sup>19</sup>. Briefly, the MTFa was obtained at each defocus position by integrating the  
135 corresponding averaged MTF curve on the spatial frequency range from 0 to 50  
136 cycles/mm (equivalent to 15 cycles per degree in the object space).

### 137 **Halo assessment**

138 The halo induced by the AcrySof® IQ Vivity™ was assessed in-vitro with a test  
139 bench of the Grupo de Óptica Aplicada y Procesado de Imagen (GOAPI, Universitat  
140 Politècnica de Catalunya BarcelonaTech, Terrassa, Spain) that has been described in  
141 detail elsewhere<sup>18-22</sup> and summarized here for the shake of conciseness. In brief, the  
142 setup consists of three parts: the illumination system, the model eye and the image  
143 acquisition system.

144 A green LED source ( $530 \pm 20$  nm) illuminated a pinhole object set optically at  
145 infinity. The model eye was formed by an artificial cornea and a wet cell with balanced  
146 salt solution where the IOL was immersed. The artificial cornea induced the same 4th-  
147 order spherical aberration for a 5.0 mm pupil at the IOL plane as the PMTF optical bench.  
148 The model eye with the IOL formed an image of the pinhole object at its best focus that  
149 was projected through a 10× infinity corrected microscope onto an 8-bit charge-coupled  
150 device (CCD) camera (Figure 1).

151 The image provided by the CCD camera (Figure 1A linear scale of intensity)  
152 consisted of the sharp and intense image of the pinhole (referred to from now on as the  
153 core) surrounded by a faint halo that becomes more evident when the image is  
154 displayed in logarithmic scale (Figure 1B). The energy of the halo and core regions were

155 computed and normalized to the total energy of the image as reported in previous  
156 studies<sup>18-22</sup>. To that extent and because the gray level of a pixel of the image is  
157 proportional to the energy impinging on that pixel (after prior calibration of the camera),  
158 the energy of the light that reaches a particular region of interest of the image (either  
159 core or halo) was obtained by integrating the gray level of all pixels belonging to that  
160 region.

161 The halo was evaluated for 3- and 4.5-mm pupil diameters in the best focus plane  
162 (0.00 D defocus). Additionally, to assess the effect of a hypothetical postoperative  
163 refractive error of 0.50 D on the halo induced, the measurements were also performed  
164 for +0.50 and -0.50D of defocus.

165 Finally, for comparison purposes we performed the same halo assessment of a  
166 standard monofocal IOL (Clareon, Alcon Labs., Inc., USA).

### 167 **Clinical outcomes**

168 The retrospective, observational study examined 60 eyes of 30 cataract patients  
169 who underwent bilateral cataract surgery with implantation of the AcrySof® IQ Vivity™  
170 (Alcon Labs., Inc., USA) at Fernández-Vega Ophthalmological Institute, Oviedo, Spain. All  
171 patients provided written informed consent, and the nature and possible consequences  
172 of the study were explained fully in accordance with the Declaration of Helsinki.  
173 Inclusion criteria were patients with cataracts, age between 65 and 85 years, corneal  
174 astigmatism  $\leq 2.00$ D, axial length ranging from 22.0 to 25.0 mm, and willingness of  
175 attending the postoperative follow-up of 6 months. Exclusion criteria were previous  
176 ocular surgery, irregular corneal astigmatism, abnormal iris, or any ocular conditions  
177 contraindicating presbyopia-correcting IOL implantation.



178 Before surgery, all patients had a complete ophthalmologic examination  
179 including manifest refraction, corneal topography-tomography (Sirius, CSO Ophthalmic,  
180 Italy), slit-lamp biomicroscopy, Goldmann applanation tonometry, and binocular  
181 indirect ophthalmoscopy through dilated pupils. Pupil diameter with distance vision was  
182 measured at two different levels of illumination using a pupillometer (Colvard; Oasis,  
183 San Dimas, CA). Axial length and anterior segment size were measured with a  
184 noncontact optical biometer (IOLMaster 700; Carl Zeiss Meditec). The SRK-T and Barrett  
185 Universal II formulas were used for IOL power calculation. The targeted refraction was  
186 emmetropia.

187 The same experienced surgeon (J.F.A.) carried out all surgeries. All eyes  
188 underwent phacoemulsification with the Centurion Vision System (Alcon Labs., Inc.,  
189 USA) using topical anesthesia. A 2.2 to 3.2 mm clear corneal incision (CCI) was performed  
190 in the steep-axis using the Callisto system (Carl Zeiss Meditec AG, Germany) to reduce  
191 preexisting astigmatism. In eyes with astigmatism less than 1.25 D, one CCI (2.2 mm)  
192 was performed while in eyes with astigmatism between 1.50-2.00 D, two opposite CCIs  
193 (3.2 mm) were carried out. All eyes underwent femtosecond laser-assisted lens surgery  
194 using the LenSx platform (Alcon, Labs., Inc., USA) to perform the anterior capsulotomy  
195 and fragment of the nucleus, and a 14C Morcher capsular tension ring (CTR) was  
196 implanted.

197 Postoperative follow-up visits were scheduled at 1-day and 1, 3, and 6 months.  
198 At six months post-surgery, the clinical protocol to evaluate the visual and refractive  
199 outcomes included the following measurements: Monocular and Binocular uncorrected  
200 distance visual acuity (UDVA) and best-corrected distance visual acuity (CDVA) at 100%  
201 contrast under photopic conditions (85 cd/m<sup>2</sup>). Binocular through-focus logMAR visual

202 acuity (defocus curve; range from -3.00 to +1.00D in 0.50D steps) was measured in  
203 patients with a monocular CDVA > 0.1 logMAR.

204 **Data analysis was performed using SPSS for Windows, version 14.0 (SPSS Inc.,**  
205 **Chicago, IL). Normality was checked with the Kolmogorov-Smirnov test. Visual and**  
206 **refractive outcomes were analyzed at the 6-month postoperative visit. Means and**  
207 **standard deviations or percentages were used to report postoperative visual and**  
208 **refractive results. The cumulative binocular UDVA and CDVA were calculated at six**  
209 **months post-surgery. For the refractive predictability, the Pearson coefficient was**  
210 **used to analyze the correlation between the attempted refractive sphere refraction**  
211 **and the achieved refractive sphere refraction.**

## 212 RESULTS

### 213 Optical performance

214 The TF MTFa curves for 3 and 4.5 mm of pupil aperture are shown in Figures 2A  
215 and 2B, respectively. For the 4.5 mm pupil, the curve shows a peak of maximum MTFa  
216 and thus, a maximum of optical quality at -0.20 D that is slightly shifted but still very  
217 close to the nominal defocus position of 0.0 D (corresponding to the best focus for  
218 distance vision) for the 20 D IOL. The MTFa value at said focus (position -0.20 D in the  
219 through-focus range) was 38.4. From that focus power, the MTFa decays monotonously  
220 for both lower (hyperopic) and higher (myopic) powers. For the 3.00 mm pupil, the IOL  
221 optical behavior significantly changed. The first finding is that the peak of maximum  
222 MTFa is lower (28.9) and it is located at -0.70D. Consequently, there is a myopic shift of  
223 0.50D from the best focal point obtained for 4.5mm pupil diameter. Moreover, the  
224 shape of the MTFa curve widens towards the myopic powers with a plateau of MTFa $\approx$ 20  
225 that reaches defocus values of -2.20 D. From this point to nearer distances (-2.20 D to -  
226 5.00 D), the MTFa curve significantly declines.

### 227 Halo assessment

228 The images of the pinhole object obtained with pupils of 3.0 and 4.5mm with the  
229 AcrySof® IQ Vivity™ are shown in Figure 3. We recall that the images are displayed in  
230 logarithmic scale only for better visualization purposes. **For the sake** of comparison,  
231 Figure 3 also includes the images obtained with a standard monofocal IOL (Clareon).  
232 Larger halos are formed by the AcrySof® IQ Vivity™ with 3.0- and 4.5 mm- pupils in  
233 comparison to the standard monofocal (Clareon, Alcon Labs., Inc., USA). However, it is  
234 worth pointing out the different behavior between both IOLs versus pupil size: while in  
235 the case of the monofocal design, the larger the pupil, the larger the halo, the AcrySof®

236 IQ Vivity™ tends instead to produce a smaller halo with the larger 4.5mm pupil.  
237 Quantitative confirmation of the above-described trends is given in Figure 4 that shows  
238 the energy in the core and halo regions (relative to the total energy of the image) for  
239 3.0- and 4.5-mm pupils for the monofocal Clareon (red bars) and AcrySof® IQ Vivity™  
240 (black bars).

241 To show the impact of defocus on the halo formed by AcrySof® IQ Vivity™, Figure  
242 5 illustrates the image obtained at the best IOL's focus, and the images with -0.50D, and  
243 +0.50D defocus and for both pupils 3.0- and 4.5mm. **Compared to the best focus, a**  
244 **defocus of +0.50 D (hyperopic defocus) induces a larger halo for both pupils, being the**  
245 **difference much more significant for 4.5mm. Whereas for -0.50 D (myopic defocus),**  
246 **the halo size is slightly smaller for both pupil sizes.**

#### 247 **Clinical outcomes**

248 This study comprised 60 eyes of 30 patients (15 men and 15 women). All patients  
249 completed the follow-up period of 6 months. Preoperative demographic data of the  
250 patients are summarized in Table 1. The mean IOL power was  $21.62 \pm 1.77$  D (range 19D  
251 to 25D)

252 The results at 6-month revealed a **satisfactory** visual acuity after the  
253 implantation of AcrySof® IQ Vivity™. The mean **postoperative monocular and binocular**  
254 **UDVA (logMAR) was  $0.18 \pm 0.17$  and  $0.10 \pm 0.12$ , respectively.** In turn, the mean  
255 **monocular and binocular CDVA (logMAR) six months after surgery was  $0.05 \pm 0.06$  and**  
256  **$0.03 \pm 0.04$ , respectively.** Figure 6 plots the cumulative binocular UDVA and CDVA. All  
257 patients achieved a binocular CDVA of 0.1 logMAR or better ( $\geq 20/25$ ) and 80% had a  
258 value of 0.0 logMAR (20/20).

259           Regarding refractive outcomes, 95% of the eyes (57 eyes) had a refractive sphere  
260 within  $\pm 0.50$  D and 100% within  $\pm 1.00$  D at six months after surgery (**Figure 7**).  
261 Preoperatively, 43.3% of the eyes had a refractive cylinder  $< 1.00$ D; whereas six months  
262 after surgery, in 78.4% of the eyes, the refractive cylinder was  $< 1.00$ D.

263           Figure 8 plots the postoperative binocular defocus curve for the cases analyzed  
264 after the implantation of AcrySof® IQ Vivity™. The curve shows one peak at the expected  
265 distance focus (0.0 D of vergence). The mean visual acuity at -0.50 and +0.50D of defocus  
266 was  $0.02 \pm 0.04$  logMAR and  $0.04 \pm 0.03$  logMAR, respectively. All patients achieved a  
267 visual acuity of 0.2 logMAR or better ( $\geq 20/32$ ) across the vergence range from +0.50 to  
268 -1.50 D (equivalent to 66 cm from the eye), and 60% of the cases 0.1 logMAR or better  
269 ( $\geq 20/25$ ) in this range of vergences. At a vergence of -2.00 D (50 cm from the eye), the  
270 visual acuity was  $0.19 \pm 0.06$  logMAR, 100% and 86.7% of the cases achieved visual acuity  
271 of 0.3 logMAR or better ( $\geq 20/40$ ) and 0.2 logMAR or better, respectively. At a vergence  
272 of -2.50 D (40 cm from the eye), the visual acuity was  $0.31 \pm 0.09$  logMAR, 100% and  
273 60% of the cases achieved visual acuity of 0.4 logMAR or better ( $\geq 20/50$ ) and 0.3 logMAR  
274 or better, respectively.

275

276

277

278

279

280

281

282           **DISCUSSION**

283           The first part of this study reported the in-vitro assessment of the new AcrySof®  
284    IQ Vivity™. Our results show that the optical performance of this IOL varied significantly  
285    depending on the pupil size (Figure 2). The TF MTFa curve for a 4.5 mm pupil (Figure 2B),  
286    showed an optical behavior similar to a monofocal IOL, with a peak of maximum MTFa  
287    (and thus, of maximum optical quality) that corresponded to the best focus of the IOL  
288    for distance. In fact, the MTFa value at this point (38.4 units) was comparable to that  
289    previously reported with a monofocal IOL and an enhanced monofocal IOL<sup>18</sup>. With  
290    regard to the TF MTFa curve with 3.0 mm pupil (Figure 2A), it showed three remarkable  
291    changes compared to that for 4.5mm. Firstly, the MTFa peak is shifted around -0.50D  
292    (myopic shift). To explain this finding, let us consider that with larger pupils, the best  
293    focus is reached when the circle of least confusion (i.e., the minimum cross-section of a  
294    symmetrical bundle of the rays focusing from the peripheral and paraxial regions of the  
295    IOL) is placed in the retina. In contrast, with a smaller pupil, the focusing depends mainly  
296    on the paraxial rays. Consequently, the myopic shift found in this IOL when closing the  
297    pupil from 4.5 mm to 3.0 mm is due to the zone that “stretches” the wavefront towards  
298    higher power which occupies the central-paraxial 2.2 mm<sup>14</sup>. The second notably  
299    difference between optical quality for 3.0- and 4.5- mm was that the maximum MTFa  
300    peak for a 3.0 mm was lower than for 4.5 mm (28.9 vs. 38.4 units) and thus, there was a  
301    reduction of the optical quality of the IOL. Usually, the smaller the pupil, the higher the  
302    optical quality (as long as the pupil diameter does not reach such a small size that  
303    diffractive effects become predominant). This paradoxical situation might also be owing  
304    to the “plateau” area that occupies the central 2.2 mm of the IOL. For a pupil size of 3.00  
305    mm, the useful IOL optical zone would be composed of about 54% “plateau area,” while

306 a monofocal-like surface would occupy the remaining area. In contrast, for a pupil size  
307 of 4.5 mm, this distribution would change to around 24% for each surface.  
308 Consequently, the potential negative impact on the optical quality of this area is  
309 expected to be higher for a pupil size of 3.0 mm than for 4.5 mm. Despite this difference,  
310 the MTFa value at the peak for 3.0 mm of pupil size was close to 30 units, which was far  
311 larger than the reported MTFa threshold from which the visual acuity might decrease  
312 (approximately 20 units)<sup>19</sup>. Finally, the TF MTFa curve measured with 3.0 mm pupil  
313 shows much clearer focus extension than the curve measured with 4.5mm pupil.

314 If we jointly analyzed both curves, we could assess the IOL behavior considering  
315 the pupil dynamic, which implies larger pupils for distance activities and a progressive  
316 pupil constriction at intermediate and near vision due to the accommodation reflex, and  
317 that usually is performed under photopic lighting conditions. Attending to this  
318 consideration, this IOL would have a behavior comparable to a monofocal IOL for  
319 distance vision and an extended range of focus up to around 2.0D, from which the  
320 optical quality would significantly decline. This behavior is consistent with the features  
321 found in the clinical defocus curve, as will be explained below.

322 Concerning the halos, overall, we found that larger halos are formed by the  
323 AcrySof® IQ Vivity™ compared to the standard monofocal analyzed. **It should be noted**  
324 **that the IOLs analyzed are made with different materials. However, as the**  
325 **comparative measurements were in-vitro, there should be no significant differences**  
326 **due to the material. The potential differences related to the IOL material could arise**  
327 **after a certain time of implantation due to material degradation, glistening.** The  
328 finding that the halo size formed by the AcrySof® IQ Vivity™ was more extensive than  
329 that of the standard monofocal is not surprising insofar as focus extension is generally

330 accompanied by some degree of halo. However, interestingly, the differences between  
331 both IOLs in the halo formed were lower for the 4.5mm pupil size. The AcrySof® IQ  
332 Vivity™ tended to produce a smaller halo with the larger 4.5mm pupil. This finding was  
333 opposite to those previously found with other design such as enhanced monofocal IOL  
334 designed to improve intermediate vision<sup>18</sup> and bifocal and trifocal IOLs<sup>12,23</sup>, where the  
335 higher the pupil size, the higher the halo. As explained before, the area occupied by the  
336 "plateau" could have a detrimental effect on the distance optical quality and halo  
337 induced by the AcrySof® IQ Vivity™ for small pupils. However, for a pupil of 4.5 mm, the  
338 contribution of the 'plateau' region has a relative lower weight thus reducing its negative  
339 effect. It is important to note that the halo is particularly bothersome for patients under  
340 mesopic and scotopic conditions, i.e., when the pupil size becomes larger. Consequently,  
341 in those conditions, this new EDOF IOL focused correctly on the core a high fraction of  
342 energy, hence seems to induce halo with low intensity, which could lead to provide, if  
343 any, few levels of photic phenomena. Our results showed that the halo formed by this  
344 new EDOF IOL is lower intensity than that previously reported with trifocal and bifocal  
345 diffractive IOL<sup>12,23</sup> and comparable to that more recently reported with a new monofocal  
346 IOL designed to enhance the intermediate vision through a modified aspheric anterior  
347 surface<sup>18</sup>.

348 It should be mentioned that slight positive or negative over refractions are not  
349 unusual after cataract surgery. Beyond the clinical implications in terms of visual acuity,  
350 which will be discussed below, it is essential to evaluate whether a slight residual  
351 refractive error may increase the halo induced by the IOL. Our results found that a  
352 defocus of +0.50D (hyperopic defocus) caused a larger halo than at the best focus,  
353 **especially for 4.5 mm of pupil size**, whereas -0.50D (myopic defocus) did not



354 substantially modify the halo size. This finding suggests that a slight postoperative  
355 hyperopic residual refractive error (although, as discussed below, it could have no  
356 significant implications in terms of visual acuity) might increase the photic phenomena.

357         The in-vitro optical performance analysis of the new AcrySof® IQ Vivity™ allows  
358 us to conclude that overall, this new EDOF IOL provides good distance optical quality  
359 and optimal at intermediate foci (up to 2.00D; equivalent to 50 cm from the eye).  
360 However, as expected, insufficient optical quality to achieve an optimal visual quality at  
361 distances closer than 40 cm. Furthermore, the halo induced has significantly lower  
362 intensity than the ones produced by trifocal and bifocal diffractive IOLs<sup>12,23</sup> and  
363 comparable to new enhanced monofocal IOL<sup>18</sup>. Based on this in-vitro analysis, we  
364 retrospectively evaluated the clinical outcomes of bilateral AcrySof® IQ Vivity™  
365 implantation in a selected sample of patients with cataracts for whom a standard  
366 monofocal IOL would have been our indication, but they were also interested in  
367 minimizing dependence on spectacles after surgery.

368         Our results, at 6 months postoperatively, showed satisfactory refractive  
369 outcomes. 95% of the eyes had a refractive sphere within  $\pm 0.50$  D and 100% within  
370  $\pm 1.00$ D. The refractive cylinder was also significantly reduced through clear corneal  
371 incisions. 78.4% had a refractive cylinder < 1.00D, whereas preoperatively was 43.3%.  
372 Despite these satisfactory refractive outcomes, it is worthy of notice that 13 eyes  
373 (21.6%) had a postoperative refractive cylinder between 1 and 1.50D, which could limit  
374 the UDVA restoration<sup>24</sup>. Although, on the other hand, a small amount of refractive  
375 cylinder can enhance the uncorrected intermediate VA<sup>25, 26</sup>.

376         Concerning distance visual acuity outcomes, six months after surgery, the mean  
377 binocular UDVA and CDVA of  $0.10 \pm 0.12$  (logMAR) and  $0.05 \pm 0.06$  (logMAR),

378 respectively. All patients achieved a binocular CDVA of 0.1 logMAR (20/25) or better.  
379 These results are similar to those recently reported by Arrigo et al.<sup>27</sup>, who evaluated the  
380 real-life experience related to the implant of AcrySof® IQ Vivity™.

381 With the analysis of the defocus curve (Figure 8), the first finding is that there is  
382 an excellent tolerance to a slight postoperative refractive error. The mean visual acuities  
383 at -0.50 and +0.50D of defocus was very close to that at the best distance focus ( $0.02 \pm$   
384  $0.04$  logMAR and  $0.04 \pm 0.03$  logMAR, respectively). However, as previously detailed,  
385 postoperative hyperopia could lead to an increase of photic phenomena. Moreover, the  
386 shape of the curve shows the extension of depth of focus. The mean visual acuity was  
387 better than 0.2 logMAR (20/32) between +1.00 and -2.00D of defocus. At a vergence of  
388 -2.50 D (40 cm from the eye), the visual acuity was  $0.31 \pm 0.09$  logMAR (20/40). These  
389 results showed that this new EDOF IOL provides a good distance visual acuity, optimal  
390 or functional up to a distance between 50-40 cm from the eye.

391 AcrySof® IQ Vivity™ IOL belongs to the EDOF IOLs family, which have as general  
392 objective to cover the gap between multifocal IOL and monofocal IOL, providing a  
393 distance visual acuity similar to the monofocal IOL and improving visual acuity at  
394 intermediate distances, causing fewer photic phenomena than trifocal and bifocal IOL.  
395 Several studies have reported visual outcomes with different EDOF IOLs<sup>13</sup>. However,  
396 different optical designs and technologies are used in the current available EDOF IOLs  
397 (small-aperture design, bioanalogic IOL, diffractive or non-diffractive optics)<sup>13</sup>. Each  
398 design has its advantages and drawbacks, making it difficult the comparison between  
399 them. However, a comprehensive study of each IOL is of particular importance so that  
400 the surgeon can face the challenge of giving the best indication for each IOL aiming to  
401 meet the patient's expectation. Based on the in-vitro optical performance results, we

402 observed that this new EDOF IOL provided a good distance optical quality, which  
403 translated into a good distance visual acuity in the clinical study. In turn, from an optical  
404 standpoint, the IOL showed an extended range of focus up to around 2.0D, with 3.0 mm  
405 pupil, which allowed obtaining in the clinical defocus curve an optimal or functional  
406 visual acuity up to a distance between 50-40 cm from the eye from which the visual  
407 acuity considerably worsened. Concerning the halo, the AcrySof® IQ Vivity™ IOL seems  
408 to induce halo with low intensity for a pupil of 4.5 mm (mesopic pupil), which could lead  
409 to cause, if any, few levels of photic phenomena. A limitation of the current study was  
410 not to evaluate the subjective symptomatology related to photic phenomena using a  
411 patient-reported outcomes validated questionnaire for that purpose. Despite this  
412 limitation, in our routine practice after cataract surgery, all patients are asked if they  
413 perceived disturbing halos and glare and how bothersome these visual disturbances  
414 were. No patients reported disturbing halos or glare. This finding agrees with a recent  
415 study that reported the real-life experience three months after AcrySof® IQ Vivity™  
416 implantation<sup>27</sup>. The authors concluded patients tolerated the IOL very well, and the  
417 haloes and glare (although they occurred in about 30% of the patients) were highly  
418 tolerated. Similar to ours, the inclusion criteria were patients with clinically relevant  
419 cataracts.

420 In summary, our findings showed that this new EDOF IOL provided a good  
421 distance optical and visual quality and yielded an extended range of focus up to around  
422 2.0D, which allowed obtaining an optimal or functional visual acuity up to a distance  
423 between 50-40 cm. Furthermore, the halo formed has significantly lower intensity than  
424 the ones produced by trifocal and bifocal diffractive IOLs. All these findings suggest that

425 this new EDOF IOL could be a good indication for cataract patients for whom, up to now,  
426 a standard monofocal IOL would have been the indication.

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444 **REFERENCES**

- 445 1. Wolffsohn JS, Davies LN. Presbyopia: Effectiveness of correction strategies. *Prog Retin*  
446 *Eye Res.* 2019; 68: 124-143.
- 447 2. Madrid-Costa D, Cerviño A, Ferrer-Blasco T, García-Lázaro S, Montés-Micó R. Visual  
448 and optical performance with hybrid multifocal intraocular lenses. *Clin Exp Optom.*  
449 2010; 93: 426-440.
- 450 3. Alfonso JF, Fernández-Vega L, Puchades C, Montés-Micó R. Intermediate visual  
451 function with different multifocal intraocular lens models. *J Cataract Refract Surg.* 2010;  
452 36: 733-739.
- 453 4. Santhiago MR, Wilson SE, Netto MV, et al. Modulation transfer function and optical  
454 quality after bilateral implantation of a +3.00 D versus a +4.00 D multifocal intraocular  
455 lens. *J Cataract Refract Surg.* 2012; 38: 215-220.
- 456 5. Ruiz-Alcocer J, Madrid-Costa D, García-Lázaro S, Ferrer-Blasco T, Montés-Micó R.  
457 Optical performance of two new trifocal intraocular lenses: through-focus modulation  
458 transfer function and influence of pupil size. *Clin Exp Ophthalmol.* 2014;42: 271-  
459 276.
- 460 6. Madrid-Costa D, Ruiz-Alcocer J, Ferrer-Blasco T, García-Lázaro S, Montés-Micó R.  
461 Optical quality differences between three multifocal intraocular lenses: bifocal low add,  
462 bifocal moderate add, and trifocal. *J Refract Surg.* 2013; 29: 749-54.

- 463 7. Xu Z, Cao D, Chen X, Wu S, Wang X, Wu Q. Comparison of clinical performance  
464 between trifocal and bifocal intraocular lenses: a meta-analysis. PLoS One. 2017;12:  
465 e0186522.
- 466 8. Jonker SM, Bauer NJ, Makhotkina NY, Berendschot TT, van den Biggelaar FJ, Nuijts  
467 RM. Comparison of a trifocal intraocular lens with a +3.0 D bifocal IOL: results of a  
468 prospective randomized clinical trial. J Cataract Refract Surg. 2015; 41: 1631-1640.
- 469 9. Montés-Micó R, España E, Bueno I, Charman WN, Menezo JL. Visual performance with  
470 multifocal intraocular lenses; mesopic contrast sensitivity under distance and near  
471 conditions. Ophthalmology. 2004; 111: 85–96
- 472 10. de Silva SR, Evans JR, Kirthi V, Ziaei M, Leyland M. Multifocal versus monofocal  
473 intraocular lenses after cataract extraction. Cochrane Database Syst Rev 2016. Art. No.  
474 CD003169
- 475 11. Zhong Y, Wang K, Yu X, Liu X, Yao K. Comparison of trifocal or hybrid multifocal-  
476 extended depth of focus intraocular lenses: a systematic review and meta-analysis. Sci  
477 Rep. 2021; 11:6699. doi: 10.1038/s41598-021-86222-1.
- 478 12. Alba-Bueno F, Garzón N, Vega F, Poyales F, Millán MS. Patient-Perceived and  
479 Laboratory-Measured Halos Associated with Diffractive Bifocal and Trifocal Intraocular  
480 Lenses. Curr Eye Res. 2018; 43: 35-42.
- 481 13. Kohnen T, Suryakumar R. Extended depth-of-focus technology in intraocular lenses.  
482 J Cataract Refract Surg. 2020; 46: 298-304.
- 483 14. Kohnen T. Nondiffractive wavefront-shaping extended range-of-vision intraocular  
484 lens. J Cataract Refract Surg. 2020; 46: 1312-1313.

- 485 15. Millán MS, Vega F. Extended depth of focus intraocular lens: Chromatic  
486 performance. *Biomed Opt Express*. 2017; 8: 4294-4309.
- 487 16. Ruiz-Alcocer J, Lorente-Velázquez A, Hernández-Verdejo JL, De Gracia P, Madrid-  
488 Costa D. Optical Performance of a Trifocal IOL and a Novel Extended Depth of Focus IOL  
489 Combined With Different Corneal Profiles. *J Refract Surg*. 2020; 36: 435-441.
- 490 17. Armengol J, Garzón N, Vega F, Altemir I, Millán MS. Equivalence of two optical quality  
491 metrics to predict the visual acuity of multifocal pseudophakic patients. *Biomed Opt*  
492 *Express*. 2020; 11: 2818-2829.
- 493 18. Vega F, Millán MS, Gil MA, Garzón N. Optical Performance of a Monofocal Intraocular  
494 Lens Designed to Extend Depth of Focus. *J Refract Surg*. 2020; 36: 625-632.
- 495 19. Vega F, Millán MS, Garzón N, et al. Visual acuity of pseudophakic patients predicted  
496 from in-vitro measurements of intraocular lenses with different design. *Biomed Opt*  
497 *Express*. 2018; 9: 4893-4906.
- 498 20. Vega F, Alba-Bueno F, Millán MS. Energy distribution between distance and near  
499 images in apodized diffractive multifocal intraocular lenses. *Invest Ophthalmol Vis Sci*.  
500 2011; 52: 5695-5701.
- 501 21. Vega F, Alba-Bueno F, Millán MS. Energy efficiency of a new trifocal intraocular lens.  
502 *J Eur Opt Soc Rapid Publ*. 2014;9: 14002. doi:10.2971/jeos.2014.14002 //
- 503 22. Vega F, Millán MS, Vila-Terricabras N, Alba-Bueno F. Visible versus near-infrared  
504 optical performance of diffractive multifocal intraocular lenses. *Invest Ophthalmol Vis*  
505 *Sci*. 2015; 56:7345-7351.

506 23. Vega F, Alba-Bueno F, Millán MS, Varón C, Gil MA, Buil JA. Halo and Through-Focus  
507 Performance of Four Diffractive Multifocal Intraocular Lenses. *Invest Ophthalmol Vis Sci.*  
508 2011; 52: 5695-701.

509 24. Berdahl JP, Hardten DR, Kramer BA, Potvin R. Effect of astigmatism on visual acuity  
510 after multifocal versus monofocal intraocular lens implantation. *J Cataract Refract Surg.*  
511 2018; 44:1192-1197.

512 25. Sawusch MR, Guyton DL. Optimal astigmatism to enhance depth of focus after  
513 cataract surgery. *Ophthalmology.* 1991; 98: 1025-9.

514 26. Serra P, Chisholm C, Sanchez Trancon A, Cox M. Distance and near visual  
515 performance in pseudophakic eyes with simulated spherical and astigmatic blur. *Clin Exp*  
516 *Optom.* 2016; 99: 127-34.

517 27. Arrigo A, Gambaro G, Fasce F, et al. Extended depth-of-focus (EDOF) AcrySof® IQ  
518 Vivity® intraocular lens implant: a real-life experience. *Graefes Arch Clin Exp*  
519 *Ophthalmol.* 2021. doi: 10.1007/s00417-021-05245-6.

520

521

522

523

524

525

526



527 **FIGURE LEGEND**

528 **Figure 1.** (A) Image of the pinhole object in linear scale of intensity obtained at the best  
529 focus position of the Vivity IOL. The energy in the core region and halo was obtained  
530 inside and outside the yellow circle respectively. (B): same image but in logarithmic  
531 scale, exclusively for halo visualization. Pupil size 3.0 mm.

532 **Figure 2.** Through focus MTFa curves obtained with the AcrySof® IQ Vivity™ IOL with (A)  
533 3.0 mm and (B) 4.5mm pupil.

534 **Figure 3.** Images of the pinhole formed at their best focus by the monofocal standard  
535 IOL Clareon (top) and AcrySof® IQ Vivity™ (bottom) with 3.0- and 4.5-mm pupils. The  
536 images are in logarithmic scale of intensity.

537 **Figure 4.** Core (A) and halo energy (B) obtained with 3.0- and 4.5-mm pupil sizes with  
538 the standard monofocal Clareon (red bars) and AcrySof® IQ Vivity™ (black bars).

539 **Figure 5.** Images of the pinhole formed at their best focus, and with defocus of -0.50D,  
540 and +0.50D by the AcrySof® IQ Vivity™ with 3.0- (top) and 4.5-mm pupils (bottom). The  
541 images are in logarithmic scale of intensity.

542 **Figure 6:** Cumulative binocular uncorrected distance visual acuity (UDVA) and corrected  
543 distance visual acuity (CDVA) at 6 months post-surgery.

544 **Figure 7: Postoperative manifest refractive sphere accuracy.**

545 **Figure 8:** Mean, binocular visual acuity (logMAR) with best correction for distance, as a  
546 function of the chart vergence. Y-axis on the right shows the Snellen feet equivalent of  
547 visual acuity, and X-axis vergence (bottom diopters and top equivalence in cm). Error  
548 bars represent the SD.

549



**Table 1.** Preoperative patients' data.


	Mean $\pm$ SD	Range [Min, Max]
<b>Age (years)</b>	76.69 $\pm$ 5.95	[65, 85]
<b>Refraction sphere (D)</b>	+0.29 $\pm$ 2.68	[-6.50, +5.0]
<b>Refraction cylinder (D)</b>	-0.96 $\pm$ 0.57	[-2.0, 0]
<b>Spherical Equivalent (D)</b>	-0.19 $\pm$ 2.67	[-7.00, +4.50]
<b>CDVA (logMAR)</b>		
Monocular	0.21 $\pm$ 0.27	[1.00, 0.10]
Binocular	0.07 $\pm$ 0.07	[0.2, 0.00]
<b>UDVA</b>		
Monocular	0.77 $\pm$ 0.48	[2.00, 0.10]
Binocular	0.51 $\pm$ 0.36	[1.40, 0.10]
<b>Minimum Keratometry (D)</b>	43.69 $\pm$ 1.40	[41.00, 46.25]
<b>Maximum Keratometry (D)</b>	44.25 $\pm$ 1.42	[41.75, 47.25]
<b>ACD (mm)</b>	2.89 $\pm$ 0.48	[1.91, 4.16]
<b>Pupil diameter (mm)</b>		
Photopic (85 cd/m <sup>2</sup> )	2.85 $\pm$ 0.58	[2.01, 3.97]
Mesopic (3 cd/m <sup>2</sup> )	4.62 $\pm$ 0.77	[2.82, 5.98]
<b>Axial Length (mm)</b>	23.47 $\pm$ 0.72	[22.06, 24.97]


D: diopters; CDVA: Corrected Distance Visual Acuity; UDVA: Uncorrected Distance Visual Acuity; ACD: anterior chamber depth; SD: standard deviation.



(A) Linear


(B) Logarithmic




















Figure 8






Click here to access/download

**Author Statement/ICMJE Form**


JRS\_Auth Stmt-FV.pdf





Click here to access/download


**Author Statement/ICMJE Form**  
JRS\_Auth Stmt-LFVC.pdf







Click here to access/download

**Author Statement/ICMJE Form**  
JRS\_Auth Stmt-DMC.pdf





Click here to access/download  
**Author Statement/ICMJE Form**  
JRS\_Auth Stmt-BAB.pdf





Click here to access/download  
**Author Statement/ICMJE Form**  
JRS\_Auth Stmt-MSM.pdf





Click here to access/download  
**Author Statement/ICMJE Form**  
JRS\_Auth Stmt-JFA.pdf

